Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Immunobiology|April 15, 2008
Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteinsAlexander Dalpke, Klaus Heeg, Holger Bartz, et al.
Vaccine|November 9, 2004
Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytesHolger Bartz, Yuri Mendoza, Miriam Gebker, et al.
Blood|August 10, 2006
Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiationHolger Bartz, Nicole M Avalos, Andrea Baetz, et al.
The Journal of Allergy and Clinical Immunology|January 10, 2004
Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infectionMarc Beyer, Holger Bartz, Katharina Hörner, et al.
European Journal of Immunology|April 19, 2008
Airway epithelial cells modify immune responses by inducing an anti-inflammatory microenvironmentAnja K Mayer, Holger Bartz, Fabian Fey, et al.
Environmental Science and Pollution Research International|March 3, 2010
Extractable organic matter of standard reference material 1649a influences immunological response induced by pathogen-associated molecular patternsKerstin Ulrich, Sabine Wölfle, Anja Mayer, et al.
International Journal of Medical Microbiology : IJMM|February 18, 2005
Micromonas (Peptostreptococcus) micros: unusual case of prosthetic joint infection associated with dental proceduresHolger Bartz, Claudia b Nonnenmacher, Christine Bollmann, et al.
European Journal of Immunology|January 27, 2011
PD-L1 expression on tolerogenic APCs is controlled by STAT-3Sabine J Wölfle, Julia Strebovsky, Holger Bartz, et al.
BMJ Open|September 14, 2021
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
The British Journal of Dermatology|December 22, 2023
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)Diamant Thaçi, Andreas Pinter, Michael Sebastian, et al.
Pageof 2